secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001193125-22-064390
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech appoints David V. Smith to Board of Directors effective March 1, 2022
--------------------------------------------------------------------------------

- Smith appointed to Board and Audit Committee effective March 1, 2022.
- Annual director retainer $40,000; Audit Committee fee $7,500; receives 28,019 stock options vesting over 3 years.
- Smith is former EVP & CFO of Five Prime Therapeutics (acquired by Amgen) with 30+ years biotech leadership.
- No related-party transactions or arrangements regarding his selection as director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312522064390/0001193125-22-064390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312522064390/d304399d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-064390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer